Daniel Watson, NP
Pain Medicine · Mount Airy, NCNPI 1730687476
Payments from drug & device makers
Across 203 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$585
- AstraZeneca$508
- AbbVie$469
- Gilead$353
- Collegium Pharmaceutical, Inc.$233
- Redhill Biopharma Inc.$195
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $585 |
| AstraZeneca | 20 | $508 |
| AbbVie(2 entities) | 32 | $469 |
| Gilead | 19 | $353 |
| Collegium Pharmaceutical, Inc. | 13 | $233 |
| Redhill Biopharma Inc. | 18 | $195 |
| Scilex Pharmaceuticals Inc. | 9 | $170 |
| Lilly USA, LLC | 7 | $168 |
| GSK | 9 | $159 |
| Boston Scientific | 2 | $138 |
| Indivior Inc. | 5 | $121 |
| Pfizer | 5 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Si-bone, Inc. | 2 | $46 |
| Abbott | 2 | $40 |
| Ardelyx, Inc. | 2 | $39 |
| Amgen | 2 | $34 |
| Philips North America LLC | 1 | $33 |
| Biodelivery Sciences International, Inc. | 2 | $27 |
| Globus Medical | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| Electromed, Inc. | 2 | $21 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,646 in reported general payments places this provider in the 45th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 372 | $390,401 |
| MounjaroTirzepatide | 287 | $343,358 |
| FarxigaDapagliflozin Propanediol | 120 | $123,786 |
| ZtlidoLidocaine | 93 | $109,834 |
| RayosPrednisone | 18 | $103,275 |
| LinzessLinaclotide | 76 | $56,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $46,184 |
| RybelsusSemaglutide | 22 | $44,488 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $32,186 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $31,306 |
| VraylarCariprazine Hcl | 16 | $25,935 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 107 | $23,542 |
| EliquisApixaban | 17 | $22,539 |
| Xtampza ErOxycodone Myristate | 61 | $21,629 |
| JardianceEmpagliflozin | 20 | $21,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $585 | $434,889394 claims |
| Lilly USA, LLCMounjaro, Trulicity | $168 | $356,419300 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $508 | $138,473143 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $170 | $109,83493 claims |
| AmgenRayos | $34 | $103,27518 claims |
| AbbVieLinzess, Vraylar | $469 | $82,22092 claims |
| GSKTrelegy Ellipta | $159 | $46,18457 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $233 | $38,07691 claims |
| Indivior Inc.Suboxone | $121 | $32,18641 claims |
| PfizerEliquis | $88 | $22,53917 claims |
| Redhill Biopharma Inc.Movantik | $195 | $14,07134 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12 | $7,15312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Mount Airy
- Leonardo KapuralWinston Salem$4.1M
- James NorthWinston Salem$3.7M
- Richard RauckWinston Salem$1.7M
- Christopher GilmoreWinston Salem$1.3M
- Binit ShahHuntersville$863K
- Jeffrey PeacockWinston Salem$553K
- Courtney AumanJacksonville$210K
- Javid BakshAsheville$202K
- David ZubLeland$168K
- Jacob WangCharlotte$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.